{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T03:07:57Z","timestamp":1771038477642,"version":"3.50.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,27]]},"DOI":"10.7759\/cureus.53080","type":"journal-article","created":{"date-parts":[[2024,1,28]],"date-time":"2024-01-28T04:46:20Z","timestamp":1706417180000},"source":"Crossref","is-referenced-by-count":3,"title":["Dupilumab-Related Diabetes Mellitus With Reversal of Symptoms in a Non-genetically Predisposed Patient"],"prefix":"10.7759","author":[{"given":"Tanner C","family":"Blaylock","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Leon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/protein\/gzaa025","article-title":"Engineering therapeutic antibodies for patient safety: tackling the immunogenicity problem","volume":"33","author":"Ulitzka M","year":"2020","unstructured":"Ulitzka M, Carrara S, Grzeschik J, Kornmann H, Hock B, Kolmar H. Engineering therapeutic antibodies for patient safety: tackling the immunogenicity problem. Protein Eng Des Sel. 2020, 33:10.1093\/protein\/gzaa025","journal-title":"Protein Eng Des Sel"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01301","article-title":"T-Cell dependent immunogenicity of protein therapeutics pre-clinical assessment and mitigation-Updated consensus and review 2020","volume":"11","author":"Jawa V","year":"2020","unstructured":"Jawa V, Terry F, Gokemeijer J, Mitra-Kaushik S, Roberts BJ, Tourdot S, De Groot AS. T-Cell dependent immunogenicity of protein therapeutics pre-clinical assessment and mitigation-Updated consensus and review 2020. Front Immunol. 2020, 11:1301. 10.3389\/fimmu.2020.01301","journal-title":"Front Immunol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/cea.13491","article-title":"Mechanisms of dupilumab","volume":"50","author":"Harb H","year":"2020","unstructured":"Harb H, Chatila TA. Mechanisms of dupilumab. Clin Exp Allergy. 2020, 50:5-14. 10.1111\/cea.13491","journal-title":"Clin Exp Allergy"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s13340-021-00526-1","article-title":"Dupilumab-related type 1 diabetes in a patient with atopic dermatitis: a case report","volume":"13","author":"Kurokawa Y","year":"2022","unstructured":"Kurokawa Y, Oikawa Y, Shimada A, Yajima K. Dupilumab-related type 1 diabetes in a patient with atopic dermatitis: a case report. Diabetol Int. 2022, 13:300-3. 10.1007\/s13340-021-00526-1","journal-title":"Diabetol Int"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.12531","article-title":"Screening for prediabetes and type 2 diabetes: US Preventive Services Task Force recommendation statement","volume":"326","author":"Davidson KW","year":"2021","unstructured":"Davidson KW, Barry MJ, Mangione CM, et al.. Screening for prediabetes and type 2 diabetes: US Preventive Services Task Force recommendation statement. JAMA. 2021, 326:736-43. 10.1001\/jama.2021.12531","journal-title":"JAMA"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2337\/db12-1398","article-title":"Definition of high-risk type 1 diabetes HLA-DR and HLA-DQ types using only three single nucleotide polymorphisms","volume":"62","author":"Nguyen C","year":"2013","unstructured":"Nguyen C, Varney MD, Harrison LC, Morahan G. Definition of high-risk type 1 diabetes HLA-DR and HLA-DQ types using only three single nucleotide polymorphisms. Diabetes. 2013, 62:2135-40. 10.2337\/db12-1398","journal-title":"Diabetes"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1177\/2042098611406318","article-title":"Immunogenicity and other problems associated with the use of biopharmaceuticals","volume":"2","author":"Tovey MG","year":"2011","unstructured":"Tovey MG, Lallemand C. Immunogenicity and other problems associated with the use of biopharmaceuticals. Ther Adv Drug Saf. 2011, 2:113-28. 10.1177\/2042098611406318","journal-title":"Ther Adv Drug Saf"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s00005-012-0189-7","article-title":"Immunogenicity to biologics: mechanisms, prediction and reduction","volume":"60","author":"Sethu S","year":"2012","unstructured":"Sethu S, Govindappa K, Alhaidari M, Pirmohamed M, Park K, Sathish J. Immunogenicity to biologics: mechanisms, prediction and reduction. Arch Immunol Ther Exp (Warsz). 2012, 60:331-44. 10.1007\/s00005-012-0189-7","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011931","article-title":"Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin","volume":"346","author":"Casadevall N","year":"2002","unstructured":"Casadevall N, Nataf J, Viron B, et al.. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med. 2002, 346:469-75. 10.1056\/NEJMoa011931","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v98.12.3241","article-title":"Thrombocytopenia caused by the development of antibodies to thrombopoietin","volume":"98","author":"Li J","year":"2001","unstructured":"Li J, Yang C, Xia Y, Bertino A, Glaspy J, Roberts M, Kuter DJ. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood. 2001, 98:3241-8. 10.1182\/blood.v98.12.3241","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17259","article-title":"Atezolizumab-induced pure red cell aplasia","volume":"193","author":"Bennett R","year":"2021","unstructured":"Bennett R, Ruskova A. Atezolizumab-induced pure red cell aplasia. Br J Haematol. 2021, 193:10. 10.1111\/bjh.17259","journal-title":"Br J Haematol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1177\/0897190019850929","article-title":"Programmed cell death-1 monoclonal antibody therapy and type 1 diabetes mellitus: a review of the literature","volume":"34","author":"Farina KA","year":"2021","unstructured":"Farina KA, Kane MP. Programmed cell death-1 monoclonal antibody therapy and type 1 diabetes mellitus: a review of the literature. J Pharm Pract. 2021, 34:133-40. 10.1177\/0897190019850929","journal-title":"J Pharm Pract"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-168468","article-title":"CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation","volume":"113","author":"Bashey A","year":"2009","unstructured":"Bashey A, Medina B, Corringham S, et al.. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood. 2009, 113:1581-8. 10.1182\/blood-2008-07-168468","journal-title":"Blood"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.5603\/EP.a2021.0053","article-title":"Pembrolizumab-induced diabetes","volume":"72","author":"Banatwalla R","year":"2021","unstructured":"Banatwalla R, Kirresh OZ, Ahmed FW. Pembrolizumab-induced diabetes. Endokrynol Pol. 2021, 72:414-5. 10.5603\/EP.a2021.0053","journal-title":"Endokrynol Pol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-325266","article-title":"Autoimmunity associated with immunotherapy of cancer","volume":"118","author":"Amos SM","year":"2011","unstructured":"Amos SM, Duong CP, Westwood JA, Ritchie DS, Junghans RP, Darcy PK, Kershaw MH. Autoimmunity associated with immunotherapy of cancer. Blood. 2011, 118:499-509. 10.1182\/blood-2011-01-325266","journal-title":"Blood"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/171390-dupilumab-related-diabetes-mellitus-with-reversal-of-symptoms-in-a-non-genetically-predisposed-patient","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:14:01Z","timestamp":1707509641000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/171390-dupilumab-related-diabetes-mellitus-with-reversal-of-symptoms-in-a-non-genetically-predisposed-patient"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,27]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.53080","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1,27]]}}}